Journal of pharmacy & bioallied sciences · 2026
Evaluation of Sharpunkha's Efficacy in Splenomegaly- A Research Report.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gurmule Rajni K, Sawarkar Gaurav R
Аннотация
INTRODUCTION: Splenomegaly, often resulting from liver cirrhosis, leads to severe hematological and structural impairments. Conventional treatments offer limited efficacy, and alternative approaches are needed.
AIM: This study investigates the therapeutic potential of Sharpunkha (Tephrosia purpurea), a traditionally recognized hepatoprotective herb, in managing splenomegaly due to liver cirrhosis.
MATERIALS AND METHODS: An in vivo experimental model was developed using thioacetamide-induced splenomegaly in Wistar albino rats, followed by the administration of Sharpunkha Panchanga Churna and Sharpunkha Panchanga Kshara. The study assessed anatomical and histological changes, liver function tests (LFT), and complete blood count (CBC) parameters. Results demonstrated that Sharpunkha Panchanga Kshara exhibited superior efficacy in reducing splenic hyperplasia and hepatic fibrosis compared to Churna, closely following the effects of Silymarin, the standard drug.
RESULT: Histological analysis confirmed improved spleen and liver architecture post-treatment. These findings validate the Ayurvedic reference of Sharpunkha as "Pleehashatru" and suggest its potential for clinical application.
CONCLUSION: Future research should focus on clinical trials to establish its therapeutic role in hepatosplenomegaly management.
AIM: This study investigates the therapeutic potential of Sharpunkha (Tephrosia purpurea), a traditionally recognized hepatoprotective herb, in managing splenomegaly due to liver cirrhosis.
MATERIALS AND METHODS: An in vivo experimental model was developed using thioacetamide-induced splenomegaly in Wistar albino rats, followed by the administration of Sharpunkha Panchanga Churna and Sharpunkha Panchanga Kshara. The study assessed anatomical and histological changes, liver function tests (LFT), and complete blood count (CBC) parameters. Results demonstrated that Sharpunkha Panchanga Kshara exhibited superior efficacy in reducing splenic hyperplasia and hepatic fibrosis compared to Churna, closely following the effects of Silymarin, the standard drug.
RESULT: Histological analysis confirmed improved spleen and liver architecture post-treatment. These findings validate the Ayurvedic reference of Sharpunkha as "Pleehashatru" and suggest its potential for clinical application.
CONCLUSION: Future research should focus on clinical trials to establish its therapeutic role in hepatosplenomegaly management.